Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Prozac could be an effective anti-viral

By Drug Discovery Trends Editor | July 30, 2012

University of California, Los Angeles researchers have come across an unexpected potential use for
fluoxetine—commonly known as Prozac—which shows promise as an antiviral
agent. The discovery could provide another tool in treating human
enteroviruses that sicken and kill people in the U.S. and around the
world.

   

Human
enteroviruses are members of a genus containing more than 100 distinct
RNA viruses responsible for various life threatening infections, such as
poliomyelitis and encephalitis. While immunization has all but
eliminated the poliovirus, the archetype for the genus, no antiviral
drugs currently exist for the treatment of enterovirus infections, which
are often severe and potentially fatal. In view of its favorable
pharmacokinetics and safety profile of fluoxetine—which is in a class of
compounds typically used in the treatment of depression, anxiety
disorders and some personality disorders—the research team found that it
warrants additional study as a potential antiviral agent for
enterovirus infections.

   

Using
molecular screening, the UCLA research team from the Department of
Pediatrics, the California NanoSystems Institute and the Department of
Molecular and Medical Pharmacology found that fluoxetine was a potent
inhibitor of coxsackievirus replication. This is one of the viruses that
include polio and echovirus that is found in the gastrointestinal
tract. Exposure to the virus causes other opportunistic infections and
diseases.

   

“The
discovery of unexpected antiviral activity of fluoxetine is
scientifically very significant and draws our attention to previously
overlooked potential targets of fluoxetine and other psychogenic drugs,”
said Robert Damoiseaux, scientific director of the Molecular Screening
Shared Resource at the California NanoSystems Institute. “Part of our
follow-up work will be the discovery of these unconventional targets for
fluoxetine and other drugs of the same class and how these targets
intersect with the known targets of this drug class.”

   

Paul
Krogstad, professor of pediatrics and molecular and medical
pharmacology, added that understanding the mechanisms of action of
fluoxetine and norfloxetine against coxsackieviruses “will add to our
understanding of enterovirus replication and lead to assessment of their
potential clinical utility for the future treatment of serious
enterovirus infections.”

   

The
research team found that fluoxetine did not interfere with either viral
entry or translation of the viral genome. Instead, fluoxetine and
norfluoxetine markedly reduced the production of viral RNA and protein.

The
study was published on July 2 in the journal of Antimicrobial Agents
and Chemotherapy
. Study authors also include Jun Zuo, Kevin K. Quinn,
Steve Kye, and Paige Cooper from the Department of Pediatrics. The study
was supported by grants from the Today’s and Tomorrow’s Children’s Fund
and the UCLA Department of Pediatrics Nanopediatrics Program.

Source: University of California, Los Angeles


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE